TY  - GEN
AU  - Amiri-Kordestani,Laleh
AU  - Blumenthal,Gideon M
AU  - Xu,Qiang Casey
AU  - Zhang,Lijun
AU  - Tang,Shenghui W
AU  - Ha,Linan
AU  - Weinberg,Wendy C
AU  - Chi,Bo
AU  - Candau-Chacon,Reyes
AU  - Hughes,Patricia
AU  - Russell,Anne M
AU  - Miksinski,Sarah Pope
AU  - Chen,Xiao Hong
AU  - McGuinn,W David
AU  - Palmby,Todd
AU  - Schrieber,Sarah J
AU  - Liu,Qi
AU  - Wang,Jian
AU  - Song,Pengfei
AU  - Mehrotra,Nitin
AU  - Skarupa,Lisa
AU  - Clouse,Kathleen
AU  - Al-Hakim,Ali
AU  - Sridhara,Rajeshwari
AU  - Ibrahim,Amna
AU  - Justice,Robert
AU  - Pazdur,Richard
AU  - Cortazar,Patricia
TI  - FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer
SN  - 1557-3265
PY  - 2015///0707
KW  - Ado-Trastuzumab Emtansine
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Drug Approval
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Female
KW  - Humans
KW  - Maytansine
KW  - Middle Aged
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Trastuzumab
KW  - United States
KW  - United States Food and Drug Administration
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1158/1078-0432.CCR-14-0012
ER  -